Loading...
ROCO
8279
Market cap74mUSD
Jul 09, Last price  
88.00TWD
1D
0.00%
1Q
-17.37%
Jan 2017
-3.65%
IPO
165.94%
Name

Syngen Biotech Co Ltd

Chart & Performance

D1W1MN
ROCO:8279 chart
P/E
8.78
P/S
1.12
EPS
10.02
Div Yield, %
5.68%
Shrs. gr., 5y
-0.02%
Rev. gr., 5y
10.25%
Revenues
2.14b
+6.10%
1,297,269,0001,311,436,0001,471,266,0001,930,594,0001,837,185,0002,013,592,0002,136,484,000
Net income
272m
+13.07%
188,765,000215,550,000237,770,000321,236,000274,827,000240,207,000271,593,000
CFO
319m
-8.21%
0220,200,000336,498,000277,484,000415,130,000348,044,000319,483,000
Dividend
Jun 26, 20255 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Established in 1988 and based in Tainan City, Taiwan, Syngen Biotech Co.,Ltd. operates globally, including in Taiwan and China, specializing in the research, development, production, and sale of a diverse array of products. Its core offerings include microbial pharmaceutical raw materials, biological pesticides, fertilizers, biochemical nutritional products, and preventive medicines. The company further manufactures dietary supplements and provides comprehensive contract manufacturing services for supplements, accommodating various formats such as sachets, liquids, tablets, cup package capsules, jellies, aluminum and glass bottles, and gummies. Syngen Biotech also develops and markets science-backed bioactive pharmaceutical ingredients (APIs) under proprietary brands including Oraltics, IMMUPHYLA, V3, ST4SanTex, GUARDSPO, benefiGANO, EXPUNERGY, and BIOJOVIAL. Additional services encompass private labelling, organic food OEM/ODM, explosion-proof extraction, brand agency, and wholesale distribution. Syngen Biotech caters to numerous industries, such as sport nutrition, beauty enhancement, baby and mother care, weight management, and digestion and detox. The company actively exports its products to approximately 20 countries worldwide.
IPO date
Nov 14, 2014
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT